Events

AI3SD Winter Seminar w/ Sia Togia

Natural Language Processing in AI-driven drug discovery; what it is, why it matters and how (not) to do it

Natural Language Processing (NLP) has been used in drug discovery for decades. However, the emergence of AI-driven drug discovery coupled with recent advances in NLP have redefined the relationship between the two fields. This talk will focus on major classes of NLP techniques used in drug discovery as well as challenges arising when creating real-world biomedical NLP systems. The talk will cover topics such as dataset selection and construction, evaluation, models, methodology, research process and structure of NLP systems in AI-driven drug discovery.

Register →





Sia Togia

Lead AI Scientist

I am a Lead AI Scientist at BenevolentAI with a focus on NLP. I have a PhD in NLP from the University of Cambridge and have spent the last six years building NLP systems in the AI industry, mostly in the biomedical domain. I specialise in Information Extraction, Information Retrieval and Knowledge Representation and have a strong interest in creating NLP systems that solve real-world problems.

More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021